Adverum Bio (ADVM) Stock Forecast, Price Target & Predictions
ADVM Stock Forecast
Adverum Bio stock forecast is as follows: an average price target of $15.50 (represents a 109.18% upside from ADVM’s last price of $7.41) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
ADVM Price Target
ADVM Analyst Ratings
Adverum Bio Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Oct 14, 2024 | Francois Brisebois | Oppenheimer | $28.00 | $7.81 | 258.51% | 277.87% |
Sep 20, 2024 | Graig Suvannavejh | Mizuho Securities | $20.00 | $7.50 | 166.67% | 169.91% |
Aug 13, 2024 | Luca Issi | RBC Capital | $12.00 | $6.64 | 80.72% | 61.94% |
Nov 11, 2022 | - | Chardan Capital | $2.00 | $0.71 | 183.65% | -73.01% |
Adverum Bio Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | 1 | 3 | 3 |
Avg Price Target | $28.00 | $20.00 | $20.00 |
Last Closing Price | $7.41 | $7.41 | $7.41 |
Upside/Downside | 277.87% | 169.91% | 169.91% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 03, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Aug 13, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
Jun 25, 2024 | Oppenheimer | - | Outperform | Initialise |
Nov 11, 2022 | RBC Capital | Sector Perform | Sector Perform | Hold |
Adverum Bio Financial Forecast
Adverum Bio Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Sep 14 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | $7.50M | - | - | - | - | - | $250.00K | - | - | $216.00K | $462.00K | $265.00K | $203.00K | $204.00K |
Avg Forecast | - | - | - | - | $131.25K | $125.00K | $106.00K | $127.50K | $92.00K | $76.67K | $76.67K | $76.67K | $108.57K | $253.33K | $265.00K | $377.50K | $320.00K | $208.80K | $376.89K | $181.31K | $213.68K | $85.68K |
High Forecast | - | - | - | - | $131.25K | $125.00K | $106.00K | $127.75K | $92.00K | $76.67K | $76.67K | $76.67K | $108.57K | $253.33K | $265.00K | $377.50K | $320.00K | $250.56K | $452.27K | $217.58K | $256.42K | $102.82K |
Low Forecast | - | - | - | - | $131.25K | $125.00K | $106.00K | $127.25K | $92.00K | $76.67K | $76.67K | $76.67K | $108.57K | $253.33K | $265.00K | $377.50K | $320.00K | $167.04K | $301.51K | $145.05K | $170.95K | $68.54K |
# Analysts | - | - | - | - | 1 | 3 | 1 | 1 | 4 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 14 | 12 | 9 | 11 |
Surprise % | - | - | - | - | - | - | - | - | 81.52% | - | - | - | - | - | 0.94% | - | - | 1.03% | 1.23% | 1.46% | 0.95% | 2.38% |
Adverum Bio EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Sep 14 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | 1 | 3 | 1 | 1 | 4 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 14 | 12 | 9 | 11 |
EBITDA | - | - | - | - | - | - | - | - | $-27.27M | $-36.55M | $-26.58M | $-27.90M | $-22.31M | $-20.19M | $-15.20M | $-13.99M | $-13.52M | $-16.74M | $-15.58M | $-15.07M | $-9.39M | $-8.21M |
Avg Forecast | - | - | - | - | $-26.25K | $-25.00K | $-21.20K | $-25.50K | $-33.73M | $-15.33K | $-15.33K | $-15.33K | $-19.76M | $-50.67K | $-53.00K | $-75.50K | $-16.93M | $-16.16M | $-12.06M | $-8.93M | $-9.86M | $-3.44M |
High Forecast | - | - | - | - | $-26.25K | $-25.00K | $-21.20K | $-25.45K | $-26.98M | $-15.33K | $-15.33K | $-15.33K | $-15.80M | $-50.67K | $-53.00K | $-75.50K | $-13.54M | $-12.93M | $-9.65M | $-7.14M | $-7.89M | $-2.75M |
Low Forecast | - | - | - | - | $-26.25K | $-25.00K | $-21.20K | $-25.55K | $-40.47M | $-15.33K | $-15.33K | $-15.33K | $-23.71M | $-50.67K | $-53.00K | $-75.50K | $-20.31M | $-19.40M | $-14.48M | $-10.71M | $-11.83M | $-4.13M |
Surprise % | - | - | - | - | - | - | - | - | 0.81% | 2384.07% | 1733.78% | 1819.80% | 1.13% | 398.51% | 286.85% | 185.37% | 0.80% | 1.04% | 1.29% | 1.69% | 0.95% | 2.39% |
Adverum Bio Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Sep 14 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | 1 | 3 | 1 | 1 | 4 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 14 | 12 | 9 | 11 |
Net Income | - | - | - | - | - | - | - | - | $-28.44M | $-37.63M | $-27.77M | $-29.20M | $-22.91M | $-18.93M | $-16.12M | $-14.95M | $-14.49M | $-17.20M | $-16.10M | $-15.39M | $-9.51M | $-8.26M |
Avg Forecast | $-25.02M | $-27.59M | $-30.58M | $-28.36M | $-27.49M | $-27.26M | $-30.60M | $-29.28M | $-35.17M | $-67.39M | $-71.59M | $-60.24M | $-19.51M | $-61.17M | $-55.26M | $-61.30M | $-16.64M | $-16.61M | $-12.46M | $-9.12M | $-9.98M | $-3.46M |
High Forecast | $-25.02M | $-27.59M | $-30.58M | $-28.36M | $-27.49M | $-20.90M | $-30.60M | $-29.28M | $-28.14M | $-67.39M | $-71.59M | $-60.24M | $-15.61M | $-61.17M | $-55.26M | $-61.30M | $-13.31M | $-13.29M | $-9.97M | $-7.29M | $-7.99M | $-2.77M |
Low Forecast | $-25.02M | $-27.59M | $-30.58M | $-28.36M | $-27.49M | $-30.44M | $-30.60M | $-29.28M | $-42.21M | $-67.39M | $-71.59M | $-60.24M | $-23.42M | $-61.17M | $-55.26M | $-61.30M | $-19.96M | $-19.93M | $-14.96M | $-10.94M | $-11.98M | $-4.15M |
Surprise % | - | - | - | - | - | - | - | - | 0.81% | 0.56% | 0.39% | 0.48% | 1.17% | 0.31% | 0.29% | 0.24% | 0.87% | 1.04% | 1.29% | 1.69% | 0.95% | 2.39% |
Adverum Bio SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Sep 14 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | 1 | 3 | 1 | 1 | 4 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 14 | 12 | 9 | 11 |
SG&A | - | - | - | - | - | - | - | - | $16.16M | $13.65M | $11.35M | $10.60M | $9.04M | $8.28M | $7.39M | $7.13M | $5.58M | $5.37M | $7.99M | $8.32M | $4.14M | $2.40M |
Avg Forecast | - | - | - | - | $3.58M | $3.41M | $2.89M | $3.48M | $2.51M | $2.09M | $2.09M | $2.09M | $2.96M | $6.91M | $7.23M | $10.30M | $8.73M | $5.70M | $10.28M | $4.95M | $5.83M | $2.34M |
High Forecast | - | - | - | - | $3.58M | $3.41M | $2.89M | $3.48M | $2.51M | $2.09M | $2.09M | $2.09M | $2.96M | $6.91M | $7.23M | $10.30M | $8.73M | $6.83M | $12.34M | $5.94M | $6.99M | $2.80M |
Low Forecast | - | - | - | - | $3.58M | $3.41M | $2.89M | $3.47M | $2.51M | $2.09M | $2.09M | $2.09M | $2.96M | $6.91M | $7.23M | $10.30M | $8.73M | $4.56M | $8.22M | $3.96M | $4.66M | $1.87M |
Surprise % | - | - | - | - | - | - | - | - | 6.44% | 6.53% | 5.43% | 5.07% | 3.05% | 1.20% | 1.02% | 0.69% | 0.64% | 0.94% | 0.78% | 1.68% | 0.71% | 1.03% |
Adverum Bio EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Sep 14 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | 1 | 3 | 1 | 1 | 4 | 4 | 6 | 4 | 4 | 7 | 4 | 3 | 7 | 9 | 14 | 12 | 9 | 11 |
EPS | - | - | - | - | - | - | - | - | $-0.29 | $-0.38 | $-0.31 | $-0.36 | $-0.31 | $-0.26 | $-0.25 | $-0.23 | $-0.23 | $-0.30 | $-0.38 | $-0.57 | $-0.38 | $-0.37 |
Avg Forecast | $-1.20 | $-1.32 | $-1.47 | $-1.36 | $-1.32 | $-1.31 | $-1.47 | $-1.40 | $-3.81 | $-3.23 | $-3.43 | $-2.89 | $-2.73 | $-2.93 | $-2.65 | $-2.94 | $-2.68 | $-0.28 | $-0.24 | $-0.23 | $-0.42 | $-0.09 |
High Forecast | $-1.20 | $-1.32 | $-1.47 | $-1.36 | $-1.32 | $-1.00 | $-1.47 | $-1.40 | $-3.81 | $-3.23 | $-3.43 | $-2.89 | $-2.73 | $-2.93 | $-2.65 | $-2.94 | $-2.68 | $-0.22 | $-0.19 | $-0.18 | $-0.34 | $-0.07 |
Low Forecast | $-1.20 | $-1.32 | $-1.47 | $-1.36 | $-1.32 | $-1.46 | $-1.47 | $-1.40 | $-3.81 | $-3.23 | $-3.43 | $-2.89 | $-2.73 | $-2.93 | $-2.65 | $-2.94 | $-2.68 | $-0.34 | $-0.29 | $-0.28 | $-0.50 | $-0.11 |
Surprise % | - | - | - | - | - | - | - | - | 0.08% | 0.12% | 0.09% | 0.12% | 0.11% | 0.09% | 0.09% | 0.08% | 0.09% | 1.07% | 1.58% | 2.48% | 0.90% | 4.08% |
Adverum Bio Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
ONCT | Oncternal Therapeutics | $1.50 | $28.00 | 1766.67% | Buy |
PASG | Passage Bio | $0.63 | $6.00 | 852.38% | Buy |
QURE | uniQure | $5.86 | $53.67 | 815.87% | Buy |
KOD | Kodiak Sciences | $3.84 | $31.60 | 722.92% | Buy |
ANTX | AN2 Therapeutics | $1.08 | $8.75 | 710.19% | Buy |
AVTE | Aerovate Therapeutics | $2.79 | $13.00 | 365.95% | Hold |
SLDB | Solid Biosciences | $5.75 | $17.50 | 204.35% | Buy |
FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
ACRV | Acrivon Therapeutics | $8.01 | $22.00 | 174.66% | Buy |
RCKT | Rocket Pharmaceuticals | $16.98 | $45.00 | 165.02% | Buy |
RZLT | Rezolute | $5.50 | $13.50 | 145.45% | Buy |
KZR | Kezar Life Sciences | $7.21 | $17.50 | 142.72% | Buy |
STOK | Stoke Therapeutics | $12.86 | $30.60 | 137.95% | Buy |
AFMD | Affimed | $3.26 | $7.50 | 130.06% | Buy |
ADVM | Adverum Bio | $7.41 | $15.50 | 109.18% | Buy |
ADAG | Adagene | $3.00 | $5.00 | 66.67% | Buy |
MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
MGTX | MeiraGTx | $5.81 | $9.00 | 54.91% | Buy |
GLMD | Galmed Pharmaceuticals | $3.24 | $5.00 | 54.32% | Buy |
ABSI | Absci | $3.92 | $6.00 | 53.06% | Buy |
RYTM | Rhythm Pharmaceuticals | $49.01 | $48.60 | -0.84% | Buy |
ADVM Forecast FAQ
Is Adverum Bio a good buy?
Yes, according to 2 Wall Street analysts, Adverum Bio (ADVM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of ADVM's total ratings.
What is ADVM's price target?
Adverum Bio (ADVM) average price target is $15.5 with a range of $2 to $28, implying a 109.18% from its last price of $7.41. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Adverum Bio stock go up soon?
According to Wall Street analysts' prediction for ADVM stock, the company can go up by 109.18% (from the last price of $7.41 to the average price target of $15.5), up by 277.87% based on the highest stock price target, and down by -73.01% based on the lowest stock price target.
Can Adverum Bio stock reach $11?
ADVM's average twelve months analyst stock price target of $15.5 supports the claim that Adverum Bio can reach $11 in the near future.
What is Adverum Bio's current price target trend?
1 Wall Street analyst forecast a $28 price target for Adverum Bio (ADVM) this month, up 277.87% from its last price of $7.41. Compared to the last 3 and 12 months, the average price target increased by 169.91% and increased by 169.91%, respectively.
What are Adverum Bio's analysts' financial forecasts?
Adverum Bio's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $489.75K (high $490K, low $489.5K), average EBITDA is $-97.946K (high $-97.896K, low $-97.996K), average net income is $-115M (high $-108M, low $-118M), average SG&A $13.36M (high $13.37M, low $13.35M), and average EPS is $-5.498 (high $-5.193, low $-5.65). ADVM's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-112M (high $-112M, low $-112M), average SG&A $0 (high $0, low $0), and average EPS is $-5.35 (high $-5.35, low $-5.35).
Did the ADVM's actual financial results beat the analysts' financial forecasts?
Based on Adverum Bio's last annual report (Dec 2019), the company's revenue was $250K, which missed the average analysts forecast of $1.22M by -79.44%. Apple's EBITDA was $-66.972M, beating the average prediction of $-17.105M by 291.53%. The company's net income was $-60.427M, missing the average estimation of $-194M by -68.91%. Apple's SG&A was $28.38M, missing the average forecast of $33.17M by -14.44%. Lastly, the company's EPS was $-0.94, missing the average prediction of $-11.203 by -91.61%. In terms of the last quarterly report (Mar 2021), Adverum Bio's revenue was $7.5M, beating the average analysts' forecast of $92K by 8052.17%. The company's EBITDA was $-27.27M, missing the average prediction of $-33.729M by -19.15%. Adverum Bio's net income was $-28.436M, missing the average estimation of $-35.171M by -19.15%. The company's SG&A was $16.16M, beating the average forecast of $2.51M by 544.04%. Lastly, the company's EPS was $-0.29, missing the average prediction of $-3.811 by -92.39%